Based on 3 analysts offering 12 month price targets for Kairos Pharma Ltd
Min Forecast
$4.00+514.44%
Avg Forecast
$8.33+1,180.03%
Max Forecast
$12.00+1,743.32%
Should I buy or sell KAPA stock?
Based on 3 analysts offering ratings for Kairos Pharma Ltd.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KAPA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates KAPA as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More
Be the first to know when Wall Street analysts revise their KAPA stock forecasts and price targets.
Is Kairos Pharma Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 3 Wall Street analysts covering (NYSEMKT: KAPA) stock is to Strong Buy KAPA stock.
Out of 3 analysts, 2 (66.67%) are recommending KAPA as a Strong Buy, 1 (33.33%) are recommending KAPA as a Buy, 0 (0%) are recommending KAPA as a Hold, 0 (0%) are recommending KAPA as a Sell, and 0 (0%) are recommending KAPA as a Strong Sell.
According to 3 Wall Street analysts that have issued a 1 year KAPA price target, the average KAPA price target is $8.33, with the highest KAPA stock price forecast at $12.00 and the lowest KAPA stock price forecast at $4.00.
On average, Wall Street analysts predict that Kairos Pharma's share price could reach $8.33 by Jun 4, 2026. The average Kairos Pharma stock price prediction forecasts a potential upside of 1,180.03% from the current KAPA share price of $0.65.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.